Theralase Technologies Inc (TLTFF)

[RWC2587]

TORONTO, ON / ACCESSWIRE / May 28, 2015 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSX VENTURE: TLT) (TLTFF), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has granted an aggregate of 4,200,000 stock options to directors and officers at an exercise price of $CAN 0.50 vesting over three years and expiring five years from date of issue.

These stock options were granted to directors and officers in compliance with the Company's 2004 Stock Option Plan approved by the shareholders of the Corporation at the Annual General and Special Meeting held on November 14, 2014.

These stock options were granted as a means of rewarding directors and officers for future service to the Corporation, including:

1) Launch of the patented TLC-2000 biofeedback therapeutic laser system with Cell SensingTM technology in 2Q2015 and

2) Commencement of the Health Canada Phase Ib human clinical study for the treatment of Non-Muscle Invasive Bladder Cancer with its patented and patent pending anti-cancer Photo Dynamic Therapy in 4Q2015.